Navigation Links
Drugs in the pipeline: new therapies that could change treatment strategies
Date:4/15/2008

y to work, you need blood vessels, Jain said. However, the current study adds evidence to a concept called normalization whereby restoring order to blood vessels inside a tumor opens up a window of opportunity for treatment.

Blood vessel normalization allows the vessels that remain to perform more efficiently. With a drug like bevacizumab, some of the tumor vasculature is pruned away immediately, but the vessels that remain become less abnormal, Jain said. These normalized vessels make the surviving cancer cells more vulnerable to the treatments that can now be delivered more efficiently. Cancer therapies in this environment should be maximally effective.

In the current study, researchers enrolled 24 patients with late-stage rectal cancer. All patients completed four cycles of therapy including bevacizumab, additional standard chemotherapy, radiation and surgery.

At four years, local control, or the absence of cancer spread beyond the original tumor site, was observed in 100 percent of patients and disease-free survival in 88 percent.

Of the 24 patients treated, five had no residual cancer. Of the 19 patients with residual disease, 12 displayed severe disease. Downstaging of the tumor was observed in 12 out of 22 observable tumors.

We had shown in previous mouse studies that normalizing blood vessels would decrease tumor activity, but the question with mouse studies is whether it will work in humans, Jain said. This is the first study to confirm the idea of the effect of normalization in patients.

Preliminary results of a Phase I study of AME-133v, an Fc-engineered humanized monoclonal antibody, in low-affinity Fc?RIIIa patients with previously-treated follicular lymphoma: LB-70

A second generation, highly targeted monoclonal antibody appears to provide benefit for some patients with follicular lymphoma for whom other treatments have failed, according to results of a phase I c
'/>"/>

Contact: Staci Vernick Goldberg
Staci.goldberg@aacr.org
267-646-0616
American Association for Cancer Research
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Circadiance Launches NEW Zzzephyr Seal 28TM 29 for Its SleepWeaver 28TM 29 ADVANCE Mask Now Available in Three Colors 60056 1Circadiance Launches NEW Zzzephyr Seal 28TM 29 for Its SleepWeaver 28TM 29 ADVANCE Mask Now Available in Three Colors 60056 2STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 1STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 2STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 3STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 4STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 5STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 6Pharmalink AB Receives Patent for Nefecon 28R 29 Principle 5674 1Pharmalink AB Receives Patent for Nefecon 28R 29 Principle 5674 2Pharmalink AB Receives Patent for Nefecon 28R 29 Principle 5674 3